New Analysis Provides Basis for a Synthetic Chikungunya Blocker-Vaccine Candidate Now Available for Testing
LONDON, Aug. 26, 2014 /PRNewswire/ — An analysis by Replikins, Ltd. of Pubmed data of the gene structures of all Chikungunya virus strains has revealed extensive conservation and sharing of specific Replikin structures back to 1953. This conservation and sharing of specific Replikin gene structures has permitted the formulation of a Synthetic Chikungunya Blocker-Vaccine™ candidate, as it did for the H5N1 influenza vaccine and the Taura Syndrome Shrimp vaccine, both of which have been found to be effective (1,2).
This Chikungunya vaccine candidate is synthesized in five days and is available freeze-dried to governments and other institutions for testing and use according to the country's regulatory bodies.
For further information:
Email 646-320-5910
References:
1. Jackwood et al. Efficacy of a Replikin Peptide Vaccine Against Low-Pathogenicity Avian Influenza H5 Virus. Avian Diseases 53:613-617, 2009.
2. Bogoch S and Bogoch ES. Prediction of specific virus outbreaks made from the increased concentration of a new class of virus genomic peptides, replikins. Nature Precedings doi:10.1038/npre.2011.6279.1